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Background: Cyclophosphamide treatment on a six-day repeating metronomic schedule induces a dramatic, innate
immune cell-dependent regression of implanted gliomas. However, little is known about the underlying mechanisms
whereby metronomic cyclophosphamide induces innate immune cell mobilization and recruitment, or about the role
of DNA damage and cell stress response pathways in eliciting the immune responses linked to tumor regression.
Methods: Untreated and metronomic cyclophosphamide-treated human U251 glioblastoma xenografts were analyzed
on human microarrays at two treatment time points to identify responsive tumor cell-specific factors and their
upstream regulators. Mouse microarray analysis across two glioma models (human U251, rat 9L) was used to
identify host factors and gene networks that contribute to the observed immune and tumor regression responses.
Results: Metronomic cyclophosphamide increased expression of tumor cell-derived DNA damage, cell stress, and cell
death genes, which may facilitate innate immune activation. Increased expression of many host (mouse) immune
networks was also seen in both tumor models, including complement components, toll-like receptors, interferons,
and cytolysis pathways. Key upstream regulators activated by metronomic cyclophosphamide include members of
the interferon, toll-like receptor, inflammatory response, and PPAR signaling pathways, whose activation may
contribute to anti-tumor immunity. Many upstream regulators inhibited by metronomic cyclophosphamide,
including hypoxia-inducible factors and MAP kinases, have glioma-promoting activity; their inhibition may
contribute to the therapeutic effectiveness of the six-day repeating metronomic cyclophosphamide schedule.
Conclusions: Large numbers of responsive cytokines, chemokines and immune regulatory genes linked to
innate immune cell recruitment and tumor regression were identified, as were several immunosuppressive
factors that may contribute to the observed escape of some tumors from metronomic CPA-induced, immune-based
regression. These factors may include useful biomarkers that facilitate discovery of clinically effective immunogenic
metronomic drugs and treatment schedules, and the selection of patients most likely to be responsive to
immunogenic drug scheduling.
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Metronomic chemotherapy utilizes drug dosages that are
lower, and are given at regular, more frequent intervals than
conventional maximum tolerated dose regimens, without
extended rest periods [1-4]. Clinical trials of metronomic
therapy commonly use cyclophosphamide (CPA; 43% of
all such trials) [5], which is typically given on a low dose
daily schedule [6,7]. Low dose daily metronomic dosing
has shown promise in terms of improved therapeutic ac-
tivity and reduced host toxicity compared to maximum
tolerated dose chemotherapy, however, large randomized
trials are required to definitively establish its therapeutic
advantages. Metronomic dosing is widely thought to act
by an anti-angiogenic mechanism [1,8], reflecting the pref-
erential sensitivity of tumor endothelial cells to low doses
of CPA and several other cytotoxics [9]. However, there is
increasing evidence for important effects of metronomic
chemotherapy on other tumor-associated cells, in particu-
lar immune cells [3,10].
Innate immunity, rather than anti-angiogenesis, can be
a key mechanism leading to major regression by metro-
nomic chemotherapy of some large, established tumors
[11], as seen in work from this laboratory in implanted
brain tumor models when CPA is delivered using an
intermittent (every 6-day) metronomic schedule [12-15].
Macrophages, natural killer cells and dendritic cells and
other bone marrow-derived innate immune cells were in-
creased in both 9L and U251 gliomas implanted in adaptive
immune (T cell and B cell)-deficient scid mice. Similar re-
sponses were achieved in immunocompetent mice, where
syngeneic GL261 gliomas can be completely regressed by
metronomic CPA delivered on a 6-day schedule [12,16].
Several cytokines and chemokines associated with mo-
bilizing innate immune response cells [17,18] were also
identified in these models of metronomic CPA-induced re-
gression, including CXCL14, IL-12β, and CXCL12/SDF1α.
In contrast, when the 6-day repeating metronomic CPA
treatment was tested in NOD-scid-gamma mice, which
unlike scid mice, have deficiencies in the innate immune
system [19,20], tumor growth delay with eventual stasis,
but not tumor regression, was achieved [12].
Intermittent metronomic CPA treatment preferentially
eliminates immunosuppressive CD11b+Gr1+ myeloid-derived
suppressor cells (MDSCs) from bone marrow and spleen
of glioma-bearing mice [14]. Tumor regression in our gli-
oma models is not, however, a secondary response to the
relief of innate MDSC suppression of innate NK cells [21]
or to the adaptive Treg cell-based suppression of innate
and adaptive cytotoxic lymphocytes reported for other
metronomic regimens [22-24]. Rather, it is a direct conse-
quence of the mobilization of innate immune cells and
their recruitment to and infiltration of the chemotherapy-
damaged tumors. Further supporting the essential role of
the innate immune system, NK cell depletion by anti-asialo-GM1 antibody treatment increases tumor take rates
and stimulates tumor growth in various human and mouse
tumor models, including allogeneic YAC-1 tumors, which
do not grow without NK depletion [25], and renders the
regression of implanted GL261 gliomas incomplete fol-
lowing metronomic CPA treatment [12,16]. Withdrawal
of anti-asialo-GM1 antibody treatment while continuing
the every 6-day metronomic CPA regimen led to repopu-
lation of the tumors by NK cells and resumption of tumor
regression [12].
The mechanisms by which metronomic CPA activates
and mobilizes anti-tumor innate immune cells and then
recruits them to the drug-treated tumors are unknown.
These mechanisms could involve tumor cell death and
DNA damage or cell stress response pathways that activate
a targeted immune response resulting in tumor clearance.
Further, predictive factors of response have been elusive,
making it difficult to optimize the dose and frequency of
metronomic drug treatment [4,5,7,26] or to predict which
tumors (and which patients) are likely to be responsive to
immunogenic metronomic scheduling, and which ones are
not [27]. To address these issues, we carried out genome-
wide transcriptional profiling of untreated and metronomic
CPA-treated human U251 tumor xenografts using human
microarrays. This enabled us to identify tumor cell-specific
factors that may elicit anti-tumor innate immunity. It also
allowed us to characterize in a comprehensive and un-
biased manner the anti-tumor innate immune response,
including immune-based signaling pathways important
for activating and mobilizing a targeted immune response.
We also conducted transcriptional profiling of metronomic
CPA-treated rat 9L and human U251 tumor xenografts
using mouse microarrays. We could thus validate metro-
nomic CPA-responsive mouse genes whose expression was
previously found to be altered in the tumor compartment
[12-16], as well as identify many previously unidentified
host immune factors, cell types, and signaling molecules
important for immune recruitment and tumor regres-
sion. Together, these findings elucidate metronomic CPA-
responsive gene networks and their upstream regulators,
and provide important insights into how intermittent
metronomic CPA scheduling activates potent anti-tumor
innate immunity leading to prolonged tumor regression.
Methods
Cell lines and reagents
CPA monohydrate was purchased from Sigma Chemical Co.
(St. Louis, MO). Fetal bovine serum (FBS) and cell culture
media were purchased from Invitrogen-Life Technologies
(Carlsbad, CA). Glioma cell lines were authenticated by and
obtained from the following sources: human U251 glioblast-
oma from the Developmental Therapeutics Program Tumor
Repository (National Cancer Institute, Frederick, MD),
and rat 9L gliosarcoma from the Neurosurgery Tissue
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37°C in a humidified, 5% CO2 atmosphere; U251 cells
were grown in RPMI 1640 and 9L in DMEM culture
medium, both of which contained 10% FBS, 100 units/ml
penicillin and 100 μg/ml streptomycin.
Tumor xenografts
Male ICR/Fox Chase immune deficient scid mice 5–6
weeks old (24–26 g) (Taconic Farms, Germantown, NY)
were housed in the Boston University Laboratory of Animal
Care Facility. Animals were treated using protocols spe-
cifically reviewed for ethics and approved by the Boston
University Animal Care and Use Committee. 9L cells (4 ×
106) or U251 cells (6 × 106) were injected s.c. on each pos-
terior flank in 0.2 ml serum-free DMEM using a 0.5-inch
29-gauge needle and a 1 ml insulin syringe. Tumor areas
(length × width) were measured twice weekly using Ver-
nier calipers (VWR, Cat. #62379-531) and tumor volumes
were calculated based on Vol = (π/6)*(L*W)3/2. Tumors
were monitored and treatment groups were normalized
(each tumor volume set to 100%) once average tumor vol-
umes reached ~500 mm3. Mice were treated with CPA
monohydrate on an intermittent metronomic schedule by
i.p. injection at 140 mg CPA/kg body weight (BW) every 6
days [11], with the dose reported here based on the non-
hydrate molecular weight of 261. Tumor sizes and mouse
body weights were measured at least twice weekly. Tumor
growth rates prior to drug treatment were similar among
all normalized groups. CPA-treated tumors were collected
6 days after either the 2nd or the 3rd CPA treatment cycle
(U251 tumors) or 6 days after the 4th treatment cycle (9L
tumors), i.e., treatment days 12, 18 and 24, respectively.
Drug-free control tumors were collected on days 6, 12,
and 18 (U251) and on days 0 and 10 (9L), where day 0 is
the first day of drug treatment.
RNA processing and microarray analysis
Total RNA was extracted from tumor tissue using TRIzol
(Invitrogen). Only high quality RNA was used in this study,
as determined by Agilent Bioanalyzer (RIN value 8 or higher
using Agilent Nano-Lab Chip Kit; Agilent Technologies,
Santa Clara, CA). Randomized RNA pools (two independ-
ent pools per treatment group; biological replicates) were
generated for both untreated and metronomic CPA-
treated tumor samples by randomly distributing tumor
RNA samples into pools, with each pool comprised of the
following: 7–8 untreated 9L tumor RNAs (pools JD1,
JD2), 4 CPA-treated 9L tumor RNAs collected 6 days after
the 4th CPA treatment (pools JD3, JD4), 8 untreated U251
tumor RNAs (pools JD5, JD6), 6–7 CPA-treated U251
tumor RNAs collected 6 days after the 2nd CPA injection
(pools JD9, JD10), or collected 6 days after the 3rd CPA in-
jection (pools JD7, JD8). Each pool was prepared by com-
bining equal amounts of RNA from each of the individualtumors comprising the pool, to give a total of 7.5 μg
tumor RNA. RNA concentrations were determined for
each pool by Nanodrop analysis (Thermo Fisher Scientific
Inc., Waltham, MA) and the RNA quality (RIN number)
was reconfirmed by Bioanalyzer analysis. Tumor RNA pools
were used in a total of 10 two-color, metronomic CPA-
treated vs. untreated control tumor hybridization microar-
rays by pairing the following pools: JD1 with JD3, and JD2
with JD4 (9L tumors; comparison A); JD5 with JD9, and
JD6 with JD10 (U251 tumors; comparison B); JD5 with
JD7, and JD6 with JD8 (U251 tumors; comparison C).
Alexa 555-labeled and Alexa 647-labeled amplified
RNA samples were hybridized to Agilent Whole Mouse
Genome oligonucleotide microarrays (4 × 44 K platform
(version 2) (Agilent Technology; platform GPL10333,
array design #026655, containing 39,429 unique probes)
for 9L tumors (comparison A, above) and U251 tumors
(comparisons B and C, above) to probe for changes in ex-
pression of host cell (mouse) RNAs. The same U251
tumor RNA pools (comparisons B and C, above) were also
analyzed on Agilent Whole Human Genome oligonucleo-
tide microarrays (4 × 44 K platform, version 2; platform
GPL10332, array design #026652, containing 34,127 unique
probes) to probe for changes in expression of (human)
tumor RNAs. Biological replicates were analyzed with dye
swaps to eliminate dye bias, as described elsewhere [28,29],
giving a total of 6 mouse arrays and 4 human arrays.
Microarray data and statistical analysis
Analysis of TIFF images of each scanned slide using
Agilent’s feature extraction software, calculation of linear
and LOWESS normalized expression ratios and initial data
analysis and p-value calculation using Rosetta Resolver
(version 5.1, Rosetta Biosoftware, Seattle, WA) [30]) were
carried out by Dr. Alan Dombkowsky at the Wayne State
University microarray facility (Detroit, MI) as described
[28,31]. The Rosetta error model provides a gene-specific es-
timate of error by incorporating two elements: a technology-
specific estimate of error and an error estimate derived from
replicate arrays [30]. The technology-specific component
utilizes an intensity-dependent model of error derived
from numerous self-self hybridizations. By including the
technology-specific estimate, the Rosetta error model
avoids false positives that occur from under-estimation of
error when a small number of replicate arrays are avail-
able, thus increasing the statistical power equivalent to
that which would be obtained with at least one additional
replicate. Furthermore, a log-ratio error estimate was de-
rived in the Rosetta error model from the individual error es-
timates of each sample (color) used in the co-hybridization.
Then, for each feature an average log ratio and associated
p-value was obtained from replicate measurements (ar-
rays) using the Rosetta error model error-weighted aver-
aging method, which weighs the ratio of each sample
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gives an averaged ratio with the smallest possible error.
The Rosetta error model has superior accuracy in detecting
and quantifying relative gene expression when compared to
other statistical methods commonly used in microarray ana-
lysis, as shown by validation with spike-in experiments [32].
The full set of normalized expression ratios and p-values
is available at the Gene Expression Omnibus web site
(http://www.ncbi.nlm.nih.gov/geo) as GEO series GSE60864,
GSE60866, and GSE60867 (GEO SuperSeries GSE60913).
For analyses, both human- and mouse array-derived gene
lists were generated based on |fold change| > 1.5 and p-
value < 10−4; these cutoff values balanced the need to
minimize false positives while maximizing microarray sig-
nal:noise. To determine microarray probe species specifi-
city, the complete sets of human and mouse microarray
probes (60 nt each) were analyzed by BLAT [33] in com-
parison to human and mouse genome sequences (hg19
and mm9) and RefmRNA and mRNA sequences down-
loaded from the UCSC genome browser. A high degree of
species specificity was apparent: 91.3% of the human
microarray probes matched human RefmRNA or mRNA
sequences (‘match’ defined as sequence identity (match
score) of ≥ 50 nt of the 60 nt microarray probe), while only
10.2% matched mouse RNA sequences. Similarly, 90.3% of
the mouse array probes matched mouse RefmRNA and
mRNA sequences (match score ≥ 50 nt), while only 9.9%
matched human RNA sequences.
Gene ontology and upstream regulator analysis
The DAVID annotation tool [34] was used to analyze sets
of metronomic CPA-responsive genes identified at each
time point and in each tumor model to discover functional
gene clusters, based on gene ontology and other gene an-
notations, that show significant enrichment (enrichment
score ≥1.3, equivalent to p ≤ 0.05). The upstream pathway
analysis module of Ingenuity Pathway Analysis (IPA) (Build
320386 M, Version 21249400) was used to calculate up-
stream regulator enrichments and to determine whether
the regulators identified are either in an activated or an
inhibited state [35]. Overlap p-values were calculated by
IPA using Fisher’s Exact Test to determine the likelihood
that the putative upstream regulator is in fact an upstream
regulator, based on the significance of the overlap be-
tween the known targets of each putative upstream regu-
lator and the identified set of regulated genes. Overlap
p-values <0.01 are considered significant by IPA; how-
ever, we increased the stringency to p < E-04 to focus
on those regulators with a high probability for upstream
regulation. For each upstream regulator that met these
cutoffs, an activation Z-score, calculated by IPA, was de-
termined by comparing the known effect of the regulator
on each target gene (activation or suppression) to the
observed changes in gene expression. Based on theconcordance between these patterns, an activation Z-
score was assigned by IPA after correcting for cases where
the regulation directions of the dataset and downstream
causal edges are skewed, enabling us to infer whether a
given upstream regulator was in an activated state (bias-
corrected Z-score > 2), an inhibited state (bias-corrected
Z-score < −2), or an uncertain state [35]. An overlap
p-value < E-04 was also applied when carrying out mech-
anistic network refinement within IPA. Upstream regulators
that were drugs and other exogenous chemicals were ex-
cluded from further consideration and are not presented.
Results
Impact of metronomic CPA treatment on tumor cell gene
expression
Microarray analysis of U251 human tumor xenografts was
carried out to identify human tumor cell genes whose ex-
pression was either increased or decreased by CPA treat-
ment on a 6-day repeating metronomic schedule. Tumor
RNA samples were analyzed on treatment days 12 and 18,
i.e., 6 days after the 2nd and 6 days after the 3rd CPA injec-
tions, respectively. Day 12 represents an early time point
in innate immune cell recruitment and tumor regression,
while day 18 is well into the tumor regression response
[12]. Tumor transcriptional profiles were assayed using
human microarrays containing ~40,000 probes represent-
ing ~20,000 human genes. Genes showing significant in-
creases or decreases in expression compared to drug-free
controls were identified: expression of 806 genes increased
at both time points while 641 genes decreased at both time
points. Further, only 8 genes showed opposite regulation at
day 12 vs. day 18, indicating a very high consistency of the
directionality of responses between time points. Many
other genes showed significant changes in expression on
day 12 only, or on day 18 only. A completed listing of all
regulated microarray probes, and their associated gene
names and annotations, expression ratios, p-values and sig-
nal intensities is provided in Additional file 1: Table S1.
Table 1 presents expression data for select examples of
U251 tumor cell genes whose responses to metronomic
CPA are beneficial to the overall therapeutic response, as
well as genes whose responses are undesirable, e.g., induction
of the tumor-promoting MMP13, the immune-inhibitory
adhesion molecule CEACAM1, and the pro-metastatic
factors LAMP3/CD208 and ACP5.
DAVID analysis [34] identified functional gene ontol-
ogy clusters significantly enriched in the sets of U251
tumor cell-expressed genes showing a consistent pattern
of increased expression at both CPA time points. High-
est enrichments were found for the gene ontology clusters
inflammatory/defense response, histone/nucleosome core,
cytokine activity and cytokine stimulus, induction/regulation
of apoptosis, and positive regulation of the (innate) im-
mune system (Table 2A; Additional file 1: Table S2A).
Table 1 Examples of U251 human tumor cell genes that constitute beneficial responses (A) or undesirable responses
(B) to metronomic CPA treatment
A. Beneficial responses
Gene U251 (day 12) U251 (day 18) Pro-tumor or Anti-tumor Activities References
Fold change p-value Fold change p-value
LUM 8.7 1.3E-06 14.1 1.7E-14 Inhibits tumor cell migration and invasion [112]
SSTR2 5.5 7.5E-23 5.9 0 Inhibits glioma proliferation [113]
IFNB1 5.5 9.3E-37 5.9 2.5E-43 Pro-apoptotic, anti-proliferative, anti-angiogenic factor; inhibits
accumulation of pro-angiogenic tumor-associated neutrophils
[114,115]
ZBP1 4.8 0 5.6 0 DNA sensor; activates IRFs, NFkB, and innate immunity;
interferon-inducible
[116-118]
XAF1 2.8 2.2E-35 5.5 0 Interferon-inducible, pro-apoptotic [119]
IFIT3 4.0 1.7E-37 5.3 7.8E-42 Interferon-inducible, pro-apoptotic [120]
DMBT1 3.3 7.0E-15 5.0 0 Tumor suppressor down-regulated in glioblastoma [121]
DDX58 2.8 6.5E-43 4.5 0 Induces interferon-I, activates apoptosis [122]
TNFSF4/OX40L 2.3 2.5E-08 3.5 2.8E-31 Increases adhesion of activated T cells at tumor site [123]
CXCL2/MIP2 −4.6 3.8E-14 −3.1 1.3E-09 Up-regulated in temozolomide-resistant glioma [124]
CXCR4 −3.6 7.4E-38 −5.0 2.0E-26 Promotes angiogenesis in glioma [125,126]
LGR5 −4.7 3.8E-43 −5.3 1.2E-39 Marker for poor prognosis in glioblastoma [127]
IL8/CXCL8 −7.6 1.5E-11 −5.5 1.1E-24 Proinflammatory cytokine; increases tumor angiogenesis,
invasion and metastasis; interferon-inducible
[128]
B.B. Undesirable responses
Gene U251 (day 12) U251 (day 18) Pro-tumor or Anti-tumor Activities References
Fold change p-value Fold change p-value
MMP13 10.1 1.1E-11 15.4 0 Promotes tumor cell proliferation and invasion [129]
CEACAM1 5.9 4.7E-29 13.2 7.7E-29 Immune-inhibitory adhesion molecule; interferon-inducible [94]
LAMP3/CD208 6.4 1.5E-30 9.6 0 Promotes metastases [130]
EREG 6.5 2.3E-25 8.5 0 Binds EGFR and induces glioma cell growth [95]
IDO1 4.8 0 6.5 0 Immunosuppressive in human glioblastoma; interferon-inducible [96]
ACP5 4.5 2.3E-33 5.0 7.2E-39 Pro-metastatic factor [131]
Shown are fold-change values (fold increases or decreases in expression compared to drug-free controls) and associated p-values derived from microarray analyses
for U251 tumors analyzed on day 12 and day 18 after initial CPA treatment.
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points were associated with extracellular signal, cell adhe-
sion, skeletal system and blood vessel development, and
extracellular matrix genes (Table 2B; Additional file 1:
Table S2B). The top up-regulated gene cluster, inflammatory
defense response, included several chemokines and che-
mokine receptors (CXCL9, CXCL10, CXCL11, CCL5, CCL26,
CCR1), interleukins and interleukin receptors (IL4, IL23A,
IL1R1, IL17RB, IL20RB), tumor necrosis factor ligand
TNFSF4, interferon IFNB1, complement components (C1QB,
C1S, C2, C3, C4B, CFB, CFH), peroxisome proliferator-
activated receptor PPARG, and Toll-like receptors TLR3
and TLR4.
Tumor-specific pathways activated by metronomic CPA
treatment
Functional gene networks were constructed based on the
sets of tumor cell genes whose expression was significantlyinduced or repressed by metronomic CPA treatment. One
such network (Additional file 2: Figure S1), which is acti-
vated on day 12 and may contribute to the early anti-
tumor actions of CPA, includes many intracellular cell
death factors, such as BIK, important for mitochondrial
rupture, death effector signaling caspases, DNA repair and
cell death signaling poly-A ribose polymerases (PARP10
and PARP12), tumor necrosis factor TNFSF10, the 20S
proteasome, and several cytokeratins, including KRT18,
which is released from CPA-treated tumors and is a bio-
marker for clinical response to therapy [36]. Genes im-
portant for extracellular presentation of cellular stresses
and activating inflammatory immune responses were also
induced at both early (day 12) and late (day 18) CPA treat-
ment times. Pathways involving tumor-expressed extra-
cellular membrane-bound chemokines CXCL9, CXCL10,
and CXCL11 were identified and show potential interac-
tions in networks translating intracellular damage to
Table 2 Enriched clusters of gene annotation terms for U251 (human) tumor genes up-regulated (A) or down-regulated
(B) by metronomic CPA treatment




A. Up-regulated tumor gene clusters
Inflammatory/defense response to wounding 9.15 63 3.91E-12
Signal peptide/glycoprotein/secreted 6.01 190 7.67E-13
Histone/nucleosome core 5.02 17 3.00E-12
Integral plasma membrane 4.29 83 1.29E-06
Cytokine activity 3.38 20 1.68E-04
Induction/regulation of apoptosis 3.26 31 7.73E-06
Response to bacterium/cytokine stimulus 2.99 21 6.36E-05
Positive regulation of (innate) immune system 2.72 29 1.72E-07
B. Down-regulated tumor gene clusters
Extracellular signal 5.04 81 2.75E-08
Cell adhesion 2.92 37 1.12E-04
Skeletal system development 2.70 22 1.24E-04
Extracellular matrix 2.61 25 1.98E-05
EGF-like 2.58 19 2.58E-06
Blood vessel development 2.54 17 8.45E-04
Analysis was based on genes that respond consistently after both 2 and 3 CPA/6-day treatment cycles (i.e., treatment days 12 and 18) at |fold-change| >1.5 and
p-value < 104. Shown are clusters with enrichment scores >2.5 whose top term contains >15 genes. Also shown is the number of genes and p-value for the top
term in each cluster. See Additional file 1: Tables S2A and S2B for a more complete listing of significant enrichment clusters and associated gene lists.
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ment and tumor cell death (Figure 1A-C). CXCL10 in-
creased almost 10-fold over untreated controls at both
time points and is centric to a network involving many
interferon and innate immune response genes, including
IFNB1, TLR4, and IDO1, an immunosuppressive factor
(Figure 1A). CXCL11 expression increased almost 14-fold,
and is tied to several chemokines important for extracellular
signaling and immune activation in addition to interferon
and TLR3 activation (Figure 1B). CXCL9 was also induced
in the metronomic CPA-treated tumor cells in association
with other extracellular immune activators: TNFSF4, MICB,
interleukins IL12, IL15, IL23, and IL17RB, and interferon
response genes (Figure 1C). MICB is one of two induced
MHC class I and DNA damage response-associated acti-
vating ligands for the NK cell receptor NKG2D; MICB
was significantly induced at both CPA time points, while a
second such factor, ULBP2, was up-regulated at the day
18 time point only (Additional file 1: Table S1).
Upstream regulator analysis
IPA’s Upstream Regulator Analysis is a powerful way to
identify putative ‘master regulators’ of complex gene ex-
pression changes, such as those induced by metronomic
CPA treatment. This analysis is particularly important
for upstream regulators that are regulated at the protein
level (e.g., by phosphorylation, or by ligand binding) and
therefore would not be identified by gene expression
microarray analysis. We implemented this analysis 1) toidentify upstream regulators of the U251 tumor genes
showing consistent responses at both metronomic CPA
time points, and 2) to determine whether the upstream reg-
ulators are activated or inhibited, based on the direction of
CPA-induced responses of their gene targets. We thus iden-
tified several interferon signaling network members as the
most significantly activated upstream regulators (IFNα,
IFNα2, IFNβ, IFNγ, IFNL1, IRF1) (Table 3); together, these
factors regulate many downstream immune response genes
(Figure 2, Additional file 2: Figure S2A). Other activated
upstream regulators include: TGM2 (transglutaminase 2),
which is associated with glioma stem-like cells [37]; the
PAF1 transcriptional complex [38]; IL27, which induces dif-
ferentiation of glioma cell to astrocytes [39] and pro-
motes anti-tumor immune responses [40] (Additional file 2:
Figures S2B and S2C); growth hormone, which increases
NK cell cytotoxicity to glioma cells [41]; and the endosta-
tin precursor COL18A1. Top upstream regulators whose
activity is inhibited by metronomic CPA include: MAPK1
and ERK1/2, which mediate cell proliferative signals; IL1
receptor antagonist IL1RN, which supports malignant gli-
oma growth [42]; HIF1A (hypoxia-inducible factor-1 and
EPAS1 (hypoxia-inducible factor-2 which mediate re-
sponses to hypoxia and can promote glioma growth [43];
NUPR1, which has a functional role in cancer cell resistance
to conventional chemotherapeutic drugs [44]; GAPDH,
which is dysregulated in several cancers, including glioma,
and may promote tumor growth [45]; NEDD9, an adhe-
sion protein that increases glioblastoma invasiveness [46];
Figure 1 (See legend on next page.)
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Figure 1 Top networks associated with U251 tumor human genes increased by metronomic CPA treatment on both day 12 and day 18 (late
responses), as determined by IPA. A) Top network for the human chemokine CXCL10, involved in innate immune activation via toll-like receptor
(TLR) and interferon (IFN) response pathways. B) Top network for the human chemokine CXCL11, involved in innate immune activation via DNA
damage, TLR, IFN, and secretory chemokine/cytokine pathways. C) Top network for the human chemokine CXCL9, involved in innate immune
activation via toll-like receptor, interleukin, and cell stress ligand MICB response pathways. Deeper shades of red-filled shapes indicate stronger up
regulation of the gene by metronomic CPA treatment, as determined by microarray analysis. Solid arrows: protein-DNA interactions; solid lines:
protein-protein; dashed arrows: regulation of gene expression; colored: related to highlighted factor(s). Shapes indicate protein family: rectangle:
receptor; square: cytokine; triangle: kinase; diamond: enzyme; oval: factor (ie., transcription); concentric circles: complex; circle: other.
Doloff and Waxman BMC Cancer  (2015) 15:375 Page 8 of 21SOCS1, a negative regulator of cytokine signaling; MAP3K7/
TAK1, a key component of NFκB and MAP kinase signaling
linked to the innate immune system [47]; RELA, which
contribute to tumor cell survival and promotes inflamma-
tion in the tumor microenvironment [48]; and TGFB1,
which increases glioma malignancy [49]. The inhibition of
these upstream regulators, which primarily have pro-
tumor functions, is consistent with the therapeuticTable 3 Upstream regulators of metronomic CPA-responsive h
Upstream regulator Molecule type










Growth hormone Protein hormone
COL18A1 Endostatin precursor







NEDD9 Cell adhesion protein





Regulators were identified by IPA of the set of U251 human tumor cell genes up-re
and day 18 times points. Shown are the upstream regulators whose activation state
based on a bias-corrected |Z-score| >2, and that meet the stringent threshold for ov
genes in the regulated gene set. More complete information, including Z-scores, lis
other upstream regulators are shown in Additional file 1: Table S3.effectiveness of metronomic CPA in this glioma model.
Other upstream regulators did not exhibit a clear pattern
of activation or inhibition (Additional file 1: Table S3).
Characterization of host (mouse) gene responses linked
to immune cell activation and tumor infiltration
Next, we used mouse microarrays to investigate the ex-
tent of host (mouse) immune cell involvement in theuman genes
























gulated or down-regulated by metronomic CPA in common at both the day 12
is reliably predicated to be activated (A) or inhibited (B) by CPA treatment,
erlap with the target gene set at p < E-04 and contain a minimum of 10 target
ts of target genes for each regulator, associated mechanistic networks, and
Figure 2 Interferon signaling upstream regulator pathway, with subcellular compartmentalization indicated. The activated upstream regulators
identified (orange) include interferons IFNα (dark blue dashed lines), IFNα2 (pink dashed lines), IFNβ (teal blue dashed lines), IFNγ (green dashed
lines), IFNL1 (orange dashed lines), and IRF1 (red solid lines), and regulate many immune responses. Shapes filled with deeper shades of red and
green denote human tumor genes that are up regulated (red) or down-regulated (green) by metronomic CPA to a greater extent as compared
to lighter shades, as indicated by microarray analysis. Key at the bottom: shapes used to indicate the molecular class of each factor.
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mouse gene responses in U251 tumors at the same two
time points analyzed on the human microarrays, and add-
itionally, at a single time point in a rat 9L glioma model,
where the innate immune response to metronomic CPA is
very similar to that of U251 gliomas, but requires 1–2 add-
itional CPA injections until robust immune cell recruitment
and tumor regression become apparent [12]. Metronomic
CPA treatment induced 326 mouse genes and repressed
288 mouse genes in common on all three microarrays.
The consistent regulation of these 614 mouse genes in
both tumor models/at all three time points indicates they
are robust responses (see Additional file 1: Table S4 for
full listing). Large numbers of other mouse genes were late
responding genes, i.e., they did not respond to metro-
nomic CPA until the second U251 time point (treatment
day 18) and also responded significantly in 9L tumors on
treatment day 24 (833 up-regulated, 823 down-regulated
genes). Only 8 mouse genes showed inconsistent (i.e.,Table 4 Enriched clusters of gene annotation terms for host (
metronomic CPA treatment in both U251 and 9L tumors
Cluster name Cluster enri






Regulation of cytokine production 6.44
Carbohydrate binding 5.64
Positive regulation of immune system process 4.69
Cytokine-cytokine receptor interaction 4.10
Lipid catabolic process 3.60
Induction of programmed cell death 3.24
Cell/leukocyte activation 3.22
B. Down-regulated mouse gene clusters
(Positive) regulation of transcription 10.3
Cell division 9.31
Repressor, negative regulation of gene expression 5.57
Cell migration 4.81
Spindle 4.58
Skeletal system development 4.30
Tube development 4.09
Transcription factor complex 3.80
Microtubule cytoskeleton organization 3.46
Sequence-specific DNA binding/Homeodomain 3.04
Analysis was based on genes that respond to metronomic CPA treatment cycles at
points, and also in 9L tumors. Shown are clusters with enrichment scores >3.0 whose t
the top term in each cluster. See Additional files 1: Table S5A and S5B for a more comopposite) patterns of regulation between the two U251
time points.
Mouse genes up-regulated in both tumor models (9L,
and at least one of the U251 tumor time points) were
enriched in gene clusters that include the following: im-
mune response, lysosome, regulation of cytokine production,
lectin/carbohydrate binding, cytokine receptor interaction,
induction of programmed cell death, leukocyte activation,
and regulation of immune effector process (Table 4A).
The up-regulated gene cluster showing the second highest
enrichment, immune response, includes many comple-
ment genes (C1qa, C1qb, C1qc, C1ra, C2, Cfb, Cfd, Cfp),
chemokines (Ccl19, Ccl24, Ccl25, Ccl3, Ccl4, Ccl6, Ccl9,
Cxcl14), toll-like receptors (Tlr1, Tlr4, Tlr7, Tlr8, Tlr13),
cell death effectors that act via apoptosis (Fas receptor lig-
and, Fasl, and tumor necrosis factor Tnfsf4 and other fam-
ily members and receptors (Tnfsf10, Tnfrsf13c,
Tnfrsf17)), cytolysis (lysozymes 1 and 2, Lyz1 and Lyz2),
and proteolytic enzyme degradation (Ctsa, Ctsb, Ctsd, Ctsh,mouse) genes up-regulated (A) or-down-regulated (B) by


























|fold-change| >1.5 and p-value < 104 at either, or both U251 treatment time
op term contains >15 genes. Also shown is the number of genes and p-value for
plete listing of significant enrichment clusters and associated gene lists.
Figure 3 (See legend on next page.)
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Figure 3 Top networks associated with mouse (host) genes induced by metronomic CPA treatment, as determined by IPA. A) Top network
showing connections between metronomic CPA-induced expression of innate immunological disease (many macrophage-related), adhesion,
infiltration, scavenger, and cytolysis genes. B) Top networks for NK cell-related innate immune function: tumoricidal and infectious disease NK
function, targeting via CXCR3 and FAS, and cytolysis via granzyme and perforin, and C), NK cell-related inflammatory disease network. Deeper
shades of red indicate stronger up regulation of the gene by metronomic CPA treatment. Solid arrows: protein-DNA interactions; solid lines:
protein-protein; dashed arrows: regulation of gene expression; colored: related to highlighted factor(s). Shapes indicate protein family: rectangle:
receptor; square: cytokine; triangle: kinase; diamond: enzyme; oval: factor (i.e., transcription); concentric circles: complex; circle: other.
Doloff and Waxman BMC Cancer  (2015) 15:375 Page 12 of 21Ctss). Mouse genes that were down-regulated by metro-
nomic CPA treatment were enriched for essential cellular
functions, including DNA binding and transcription, cell
division, cell migration, tube/epithelium development, and
cytoskeleton organization (Table 4B). A complete listing
of significant gene clusters is presented in Additional
file 1: Tables S5A and S5B.
Host immune system-related pathways activated by
metronomic CPA
We used IPA to construct functional networks of host
(mouse) genes whose expression was significantly altered
by metronomic CPA treatment. Several of the net-
works centered on immune cell function. One network
highlighted immunological disease factors, many of which
are macrophage-associated, including macrophage marker
Cd68, scavenger receptor class A molecules (i.e., Colec12),
macrophage effector lysozymes 1 and 2 (Lyz1 and Lyz2),
inflammatory response phospholipases (Pla2, Pla2g2d,
Pla2g2e, Cpla2), macrophage-produced lymphocyte mito-
gen Il1, receptor responsiveness factor Ptpn22, phagocyt-
osis regulator Gas6, and the pro-infiltration extracellular
matrix remodeling enzymes Hpse and Mmp2 (Figure 3A).
Two other networks grouped NK cell-related genes. The
first network shows tumoricidal and infectious disease-
related NK factors, including granzymes A and B (Gzma,
Gzmb), perforin (Prf1), Fas death receptor (Fas), Fas-
mediated apoptosis gene Olr1, NK cell-expressed chemo-
kine receptor Cxcr3 (the known interacting receptor for
chemokines CXCL9, CXCL10, and CXCL11), MHC class
I regulated NK marker Klrg1, interferon-activated genes
(Ifi202b, Oas1), NK cell-expressed Ly6a and Sema4d, and
lymphocyte-homing factors Stab2 and Nov (Figure 3B and
Figure 3C). The second network displays inflammatory disease
NK cell markers NKp46 (Ncr1), migration factors Cxcl14 and
Xcl1, NK perforin cytotoxicity regulator Klra4, and NK
adhesion molecules (Prelp, Cd96) (Figure 3B and Figure 3C).
Upstream regulators of metronomic CPA-induced
anti-tumor immunity
We analyzed the metronomic CPA-responsive mouse
(host) gene sets to elucidate potential upstream regula-
tors, including transcription factors and cytokines that
may regulate anti-tumor innate immunity induced by
metronomic CPA treatment. The transcription factorsPPARA, PPARG, NR1H3/LXRα and NR1H2/LXRβ were
prominent as upstream regulators of mouse genes that
respond to metronomic CPA early, i.e., 6 days after the
2nd CPA cycle in the U251 model (Additional file 1:
Table S6 and Additional file 2: Figure S3). PPARG ago-
nists exhibit anticancer activity in glioma models [50],
and increases in PPAR function have been implicated in
persistent inflammation [51], while agonists of LXR pro-
mote glioblastoma cell death [52]. Upstream regulators
inhibited at the same early time point include CSF2,
which supports M1 macrophage polarization [53], and
CD38, whose loss attenuates glioma progression [54,55]
(Additional file 1: Table S6). When all mouse genes show-
ing concordance in both tumor models at the time
when CPA-induced tumor regression is well underway
(i.e., treatment day 18 in U251 tumors and day 24 in 9L
tumors) were considered, many more upstream regulators
were identified (Table 5; Additional file 1: Table S7). The
activated upstream regulators include factors related to
inflammatory responses (IL6, the NF B-activating kin-
ase IKBKB, NLRP3 inflammasome, and mir-223), inter-
feron signaling and action (IFNAR, IFNG, IFNα/IFNβ,
STAT1, IRF3, IRF5, IRF7), and TLR signaling associ-
ated with innate immune responses (TLR3, TLR4, TLR9,
TICAM1, DDX58, MYD88) (Figures 4, 5, and Additional
file 2: Figures S4 and S5). Other upstream regulators of
the responding mouse genes include: IL12 and IL18,
which stimulate macrophages and NK cells to produce
IFNγ and induce glioma cell death [56]; NFATC2, which
is important for inducing gene transcription during an im-
mune response; DOCK8, required for NK cell function
[57]; SASH1, whose increased expression has been related
to inhibition of U251 glioma cell growth, proliferation,
and invasion [58]; NOS2, a marker for M1 (anti-tumor)
macrophages; BNIP3L, a pro-apoptotic factor [59]; SPI1,
important for myeloid cell development an innate immun-
ity [60]; and FADD, which is recruited to activated cell
death receptors [61]. These activated upstream regulators
can be considered as contributing to the antitumor actions
of metronomic CPA. By contrast, another activated up-
stream regulator, SAMSN1, which is highly expressed in
glioblastoma, is associated with poor prognosis for sur-
vival [62]. SAMSN1 has also been shown to suppress B
cell activation [63]. However, we previously observed no B
cell involvement in our immune competent C57BL/6,
Table 5 Upstream regulators of metronomic CPA-responsive mouse genes
Upstream regulator Molecule type p-value of overlap # of target genes
A. Activated upstream regulators (mouse gene targets)
IFNAR Interferon receptor 5.34E-14 31
IRF3 Transcription regulator 5.62E-12 28
IFNG Interferon 2.55E-11 80
IL12 (complex) Cytokine 1.04E-10 24
STAT1 Transcription regulator 1.32E-10 37
IRF7 Transcription regulator 1.64E-10 23
IFN alpha/beta Interferon 3.98E-09 20
NFATC2 Transcription regulator 4.77E-09 26
IFNB1 Cytokine 9.37E-09 34
TLR4 Toll-like receptor 3.19E-08 42
DOCK8 other 4.22E-08 21
SASH1 other 7.34E-08 21
TICAM1 Adapter for TLR3 1.05E-07 28
ITK Kinase 1.52E-07 22
SAMSN1 other 2.20E-07 23
mir-223 MicroRNA 3.67E-07 24
DDX58 Enzyme 1.15E-06 14
IL6 Interleukin 6 1.22E-06 30
SPI1 Transcription regulator 1.31E-06 19
IKBKB Kinase that activates REL/NF B 3.41E-06 31
NOS2 Nitric oxide synthase; M1 macrophage marker 3.83E-06 30
MYD88 Adapter for TLRs 7.34E-06 32
TLR3 Transmembrane receptor 8.10E-06 27
BNIP3L Pro-apoptotic factor 9.69E-06 15
TLR9 Transmembrane receptor 1.33E-05 25
NLRP3 Inflammasome 1.59E-05 15
IRF5 Transcription regulator 2.22E-05 12
PPARG Ligand-dependent nuclear receptor 5.21E-05 40
IL18 Cytokine 6.86E-05 11
FADD Transmembrane receptor adapter protein 7.33E-05 15
CD44 Enzyme 7.53E-05 22
CDKN2A Transcription regulator 8.10E-05 20
B. Inhibited upstream regulators (mouse gene targets)
CSF2/GM-CSF Cytokine 3.82E-15 45
TRIM24 Transcription regulator 8.10E-13 32
PTGER2 G-protein coupled receptor 1.65E-09 26
DNASE2 Enzyme 4.26E-08 14
ACKR2 G-protein coupled receptor 4.87E-08 15
SOCS1 other 1.26E-07 20
mir-21 MicroRNA 1.67E-06 25
TGFB1 Growth factor 9.61E-06 19
MYC Transcription regulator 1.46E-05 24
Upstream regulators were identified by IPA analysis of the set of mouse genes up-regulated or down-regulated by metronomic CPA in common in U251 tumors
after three metronomic CPA treatments (day 18) and in 9L tumors after four metronomic CPA treatments (day 24), as described in Methods. Shown are the upstream
regulators whose activation state is reliably predicated to be activated (A) or inhibited (B) by CPA treatment, with other details as described in Table 3. More complete
information, including Z-scores, lists of target genes for each regulator, associated mechanistic networks, and other upstream regulators are shown in Additional file 1:
Table S7.
Doloff and Waxman BMC Cancer  (2015) 15:375 Page 13 of 21
Figure 4 Downstream target network for the predicted upstream regulators of the mouse genes IL15 (dashed dark blue lines), IL18 (dashed red
lines), TLR3 (dashed gold lines), TLR9 (dashed magenta lines), IKBKB (dashed green lines), and NFKB (dashed teal lines), showing multi-layer cell
signaling and cross-talk between regulators, as well as downstream signaling and up- or down-regulation of genes identified on the mouse array
as being responsive to metronomic CPA treatment. Genes and upstream regulators shown are only those that are common across tumor models
at both late time points (U251 tumors on day 18 and 9L tumors on day 24). This network identifies potential signaling in tumor cell death-induced
pathways, such as interferon, cytokine, tumor necrosis factor, TLR, and NFkB signaling. Deeper shades of red and green denote human tumor genes
that are up-regulated (red) or down-regulated (green) by metronomic CPA to a greater extent as compared to lighter shades, as indicated by
microarray analysis. Key at the bottom: shapes used to indicate the molecular class of each factor, as defined in Figure 3.
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regulators inhibited by metronomic CPA in both tumor
models include: CSF2 (GM-CSF), which induces differen-
tiation of brain macrophages into M1 anti-tumor macro-
phages [64], but has also been shown to be
neuroprotective [65], and perhaps its down-regulation is
important for tumor ablation in these brain tumor models;
TRIM24, which promotes glioma progression and en-
hances chemoresistance [66]; DNASE2; G-protein coupledreceptors PTGER2 and ACKR2; SOCS1, an inhibitor of
cytokine signaling; the oncomir mir-21; growth factor
TGFB; and the oncogene Myc.
Discussion
Chemotherapy given as a single dose can stimulate anti-
tumor immune responses, but this finding has not trans-
lated well to the cancer clinic, where many conventional
chemotherapy regimens are toxic to T cells, NK cells and
Figure 5 Downstream target network for the predicted mouse (host) upstream regulators DDX58 (magenta), FADD (dark blue), MAVS (red),
STAT1 (green), and IRF7 (teal blue), showing multi-layer cell signaling and cross-talk amongst regulators, as well as downstream signaling and
up- or down-regulation of genes identified on the mouse array following metronomic CPA treatment. Genes and upstream regulators show only
those that are common to both late time points (day 18 and day 24) across the U251 and 9L models. This network identifies potential signaling
in tumor cell death-induced immunogenic pathways, such as interferon, cytokine, tumor necrosis factor, and cytolysis (i.e., killer cell lectin, granzyme
and perforin) signaling. Deeper shades of red and green denote human tumor genes that are up-regulated (red) or down-regulated (green)
by metronomic CPA to a greater extent as compared to lighter shades, as indicated by microarray analysis. Key at the bottom: shapes
used to indicate the molecular class of each factor.
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Recent studies from this laboratory have shown that ad-
ministration of CPA on a metronomic, 6-day repeating
schedule activates a potent anti-tumor response in several
implanted glioma models leading to major regression of
large tumors that is dependent on innate [12-15] as well
as adaptive [12,16] immune cells. This strong therapeutic
response may involve immunogenic cell death, which can
be activated by CPA and several other cytotoxic anti-cancer drugs [69,70]. Here, we conducted genome-wide
transcriptional profiling of implanted U251 human glio-
blastoma and 9L rat gliosarcoma to further characterize
this response and to obtain novel insights that help eluci-
date the mechanisms by which metronomic CPA activates
innate anti-tumor immunity.
Several of the mouse (host) gene clusters that were ei-
ther activated or repressed in the tumor compartment
by metronomic CPA treatment (Table 4) are similar to
Doloff and Waxman BMC Cancer  (2015) 15:375 Page 16 of 21those found in bone marrow and spleen of tumor-bearing
mice when a single CPA injection was combined with
adoptive cell transfer of lymphomonocytes from tumor-
vaccinated syngeneic mice [71]. Maximal anti-tumor ac-
tivity against metastatic Friend leukemia 3CL-8 cells was
seen when lymphomonocytes derived from spleens of the
tumor-immunized mice where transferred within 24 hr
after a single CPA injection, with efficacy being lost when
cells were transferred after 48 hr. The authors reported a
“cytokine storm” in bone marrow, and to a lesser extent in
spleen and in peripheral blood mononuclear cells of the
CPA-treated mice, which may contribute to the observed
anti-tumor response. In the present study, we characterize
the potent immune stimulatory actions of CPA in the
tumor compartment of two glioma models, where intermit-
tent administration of CPA on a 6 day repeating metro-
nomic schedule is sufficient to activate and mobilize the
host immune system, resulting in potent anti-tumor activity
and major tumor regression without the need for combin-
ation with adoptive immunotherapy or immunomodulatory
agents.
The present study validates our previous findings that
metronomic CPA recruits and/or induces many innate
immune cell factors, as seen both at the level of RNA
and protein in the CPA-treated tumors [12-16]. These in-
clude the death receptor Fas, which stimulates macrophage
activation [72,73] and acts as an important mediator of
interactions between NK cells and cells marked for de-
struction [74]. Macrophage marker CD68, platelet marker
PF4, dendritic cell markers CD74, implicated in DC
migration [75], and CD209 (DC-SIGN), important for
antigen presentation, were also increased, as were NK
cell markers NKp46 (Ncr1) and NK1.1 (Klrb1), NK
activating receptor NKG2D (Klrk1), NK effector gran-
zymes A and B, and perforin, which are essential for cyto-
toxic lymphocyte-mediated cell death [76]. Cytokine
and chemokine immune attractants CXCL14, IL12β and
CXCL12/SDF1α were also increased by metronomic
CPA treatment, implicating chemokine and cytokine
gradients in stimulating leukocyte and lymphocyte mi-
gration [17,18]. These targets were all validated by host
(mouse) microarray analysis and shown to be up-
regulated by metronomic CPA in both U251 and 9L
gliomas.
The present study also identified many additional genes
and pathways that can contribute to the strong immune
response activated by metronomic CPA treatment. Factors
involved in immune-mediated cytolysis were identified, in-
cluding the macrophage cytolytic effectors lysozymes 1
and 2 (Lyz1 and Lyz2) [77], corroborated in a recent study
from our group [14], as well as several other NK cell
effector granzymes [74] not investigated in our earlier
studies of metronomic CPA treated-gliomas. Many add-
itional macrophage-related genes were increased in themetronomic CPA-treated tumors (Figure 3A), supporting
macrophage involvement in metronomic CPA-induced
tumor regression. These include Col8A1 and Col8A2, col-
lagen factors important for macrophage adhesion, and
macrophage-associated phospholipases (Pla2g2d, Pnpla2),
which are inducible by inflammation-induced interferon-
secretion [78]. Other factors induced in the treated gliomas
include scavenger receptor Colec12, which is important in
host defense responses, matrix metalloproteinase-2 (Mmp2)
and heparanase (Hpse), important for extracellular matrix
remodeling and macrophage infiltration [79], Ptpn22,
a phosphatase important for macrophage responsiveness,
and Gas6, which regulates macrophage phagocytosis
(Figure 3A). Other NK cell markers increased in the
metronomic CPA-treated tumors include Ly6a, Sema4d
(Cd100), Klrg1, an inhibitory NK cell receptor associated
with memory NK cells [80], Stab2, which is important for
lymphocyte homing and cell adhesion [81], the NK adhe-
sion ligand Cd96 [82], and regulators of NK cytotoxicity,
such as Sh2d1a and Klra5 [83,84] (Figure 3B and Figure
3C). Innate immune cell-associated genes Tmsb10 and
Tmsb4x, which are important for cell migration and adhe-
sion, were strongly induced (Figure 3B, left and right). Co-
agulation factor 3 (F3), which may contribute to an
immune-mediated inflammation response [85], was also
significantly up-regulated in the metronomic CPA-treated
tumors. Further, C3 and other complement components
were significantly increased by metronomic CPA treat-
ment in both tumor models (Additional file 2: Figure S7)
and likely contribute to the observed innate immune acti-
vation and clearance of dying tumor cells [86]. Another
induced complement factor, C1q, is synthesized by monocyte-
derived macrophages and dendritic cells and is important
for opsonization and forming membrane lytic complexes
[87], and perhaps is employed to clear CPA-damaged tumor
cells. Finally, many factors related to immune-mediated
proteolysis and cell death, such as C1-esterase inhibitor
(Serping1), lymphotoxin A (TNFβ, Lta), and lymphocyte
cytosolic protein 2 (Lcp2), were identified as late respond-
ing mouse genes in the U251 and 9L models, while several
cathepsins (Cts genes) were increased both at early and at
late time points in both tumor models.
Upstream regulator analysis identified several type I
and type II interferon signaling network members as be-
ing activated and most significantly associated with gene
responses to metronomic CPA treatment (Tables 3 and 5).
Many gene expression changes in the tumor compartment
were thus linked to interferon signaling pathways (Figure 2,
Additional file 2: Figure S6A and S6B) [88]. Examples in-
clude interferon–activated genes (Oas, Oas1, Gpnmb), genes
associated with interferon-induced immune-mediated
apoptosis of target cells (Olr1, Pml, Fas, Fasl) [89], and
many interleukins, chemokines and cytokines involved in
inflammation-based immune activation, proliferation, and
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Ccl family members, Xcl1, interleukins 15 and 18 (IL15,
IL18), and interferon-1, whose secretion can potentiate
IL15 expression (Additional file 2: Figure S6B). Interferons
exert many immune regulatory functions and can enhance
the anti-tumor activity of CPA [90]. Upstream regulators
of the tumor-associated mouse genes significantly altered
by metronomic CPA treatment include DDX58, as well as
FADD and MAVS. DDX58 is a pattern recognition recep-
tor [91] that signals through FADD and MAVS (Figure 5)
and may contribute to the observed anti-tumor immune
responses. FADD is important for innate immune-based
host defense [92] and signals through MAVS (Figure 5),
which induces innate immunity by activating transcription
factors IRF3 and IRF7, both of which increase type I inter-
feron production [93]. Mouse cell-expressed TLR3 and
TLR9, strongly induced by metronomic CPA, were identi-
fied by upstream regulator analysis as being involved in
interferon response pathway activation (Figure 4).
Many other activated upstream regulators identified
here (Tables 3 and 5) are also associated with anti-tumor
immune responses. Examples include IL27, which pro-
motes anti-tumor immunity [40], and growth hormone,
which increases NK cell cytotoxicity to glioma cells [41].
Further, many of the inhibited upstream regulators iden-
tified (Tables 3 and 5) have strong pro-tumor activities
(e.g., TGFB1, which increases glioma malignancy [49]),
consistent with the overall strong anti-tumor responses
that we have seen in the metronomic CPA-treated gli-
omas. However, not all of the gene expression changes
induced by metronomic CPA are associated with benefi-
cial responses. Select examples of undesirable tumor cells
gene responses, shown in Table 1B, include the induction of
CEACAM1, an interferon-inducible immune-inhibitory ad-
hesion molecule [94], EREG, which induces glioma cell
growth [95], and IDO1, an interferon-inducible immuno-
suppressive factor that is particularly active in glioma [96].
Undesirable responses involving upstream regulators of
mouse genes were also observed, including activation of
SAMSN1, which is associated with poor prognosis for sur-
vival in glioblastoma [62]. Further study is required to
determine whether these are feedback inhibitory (compen-
satory) responses, and how they may impact the overall
anti-tumor response to metronomic CPA treatment.
Recruitment of the innate immune system to metro-
nomic CPA treated gliomas [12-14] is likely stimulated by
tumor cell damage or stress response, with a critical level
of DNA damage or cellular stress threshold being required
to initiate a robust anti-tumor immune response, as sug-
gested by the steep dose–response curve for metronomic
CPA activation of an innate immune response in 9L gli-
omas [13]. Some of these effects are drug and tumor
model dependent: 9L tumors do not begin to regress until
the third cycle of every 6-day metronomic CPA treatment[11,97], U251 tumors begin to regress immediately after
the first CPA injection [12], and GL261 tumors regress
around the time of the second treatment cycle [12,15,16].
Since the regression of these gliomas is at least in part
dependent on innate immunity, these findings suggest
that anti-tumor immunity is triggered by a different drug-
dependent kinetic of induced damage or stress in each
tumor model. Several candidate pathways can be consid-
ered, including DNA damage, heat shock, cellular senes-
cence, wounding and stress responses [98]. Specific examples
include genes associated with oxidative stress (H2-M3,
KLKR1, and TLR4; Additional file 1: Table S5A), retinoic
acid (BMP4, CD38, MICB, IGFBP7, and KLF4; Additional
file 1: Table S2A), and DNA damage response (p53 in-
ducible protein Trp53inp1, Mgmt, Casp1, and Casp10;
Additional file 1: Table S5A), all of which were induced
by metronomic CPA treatment.
Metronomic CPA induced more than 30 genes important
for induction of apoptosis, as seen in both human U251
tumor cells (human array), as well as in host cells of mice
bearing U251 or 9L gliomas (mouse array) (Additional
file 1: Tables S2A and S5A), consistent with our earlier
finding that CPA kills 9L glioma cells by activating caspase
9-dependent apoptosis [99]. However, apoptosis-independent
mechanisms of CPA-induced tumor cell death have been
described, and may contribute to tumor regression [100].
Apoptosis-independent (necrotic) pathways that link
macrophage-associated immunity to CPA-damaged tu-
mors have been identified [100], and CPA-induced secre-
tion of HMGB1 protein, a hallmark of immunogenic cell
death [101] that may be a critical step in the activation
of an anti-tumor immune response, independent of an
intracellular apoptotic cascade [69,102], has been reported
[90,100]. Of note, the NK cell-associated receptor for
HMGB1, Rage, was induced in the metronomic CPA-
treated tumors (Figure 3B and Figure 3C). Metronomic
CPA treatment also induced a core set of death-related
genes that may be important for innate and/or adap-
tive immune activation by damaged tumor cells, in-
cluding Sp110, Mx1, Mx2, Ebi3, Eomes, Tnfsf4, Gdf15,
Ddx58, and Dhx58 (Figure 1A-C, Additional file 1:
Tables S1 and S4 and Additional file 2: Figure S8B).
PPARγ expression was increased almost 5-fold in metro-
nomic CPA-treated U251 tumor cells, and this could con-
tribute to the responsiveness of these brain tumors to
metronomic CPA. PPARγ is linked to many apoptosis and
interferon-related genes. In particular, IPA pathway ana-
lysis associated PPARγ with CIDEC, a known apoptosis in-
ducer, and with STAT1, which is important for interferon
and killer cell immune stimulation (Additional file 2:
Figure S4C), as well as interleukin-4 and cathepsin C
(Additional file 2: Figure S3). PEDF, which is strongly
induced in metronomic CPA-treated 9L and U251 tu-
mors [12], induces p53-mediated apoptosis through PPAR
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angiogenic activity of metronomic chemotherapy by up-
regulating endothelial cell expression of CD36, a receptor
that binds thrombospondin-1 and initiates the extrinsic
pathway of apoptosis [104]. Furthermore, combination of
low-dose trofosfamide (a CPA derivative) with the PPAR
antagonist pioglitazone and a COX-2 inhibitor resulted in
tumor regression or tumor growth stasis and general im-
provements in patient outcome [104].
Many NK cell receptor ligands are up-regulated on the
surface of cancer cells in response to cellular stresses,
damage or other stimuli [98], which stimulate anti-tumor
immunity when detected by NK cell surface receptors,
such as NKG2D and NKp46 [98,105]. In accordance with
our earlier qPCR data [12], the human DNA damage re-
sponse NKG2D activating ligand MICB was significantly
increased in U251 tumors at both early (day 12) and late
(day 18) time points (Figure 1C). A second human DNA
damage response NKG2D ligand, ULBP2, was induced in
the metronomic CPA-treated U251 tumors, but only at
day 18, suggesting that MICB, and not ULBP2, contributes
to the early onset of U251 tumor regression following
metronomic CPA treatment. Mouse (host) microarray ana-
lysis showed a significant increase in the NK cell damage
response receptor CXCR3, which binds tumor-cell specific
membrane-bound activation ligands CXCL9, CXCL10, and
CXCL11 [106], all of which were also increased on the hu-
man array. Other immune-activating receptors increased
by metronomic CPA treatment include pattern recogni-
tion receptors important for distinguishing self from non-
self antigens, including toll-like receptors (human tumor
cell-expressed TLR3 and TLR4, and mouse cell-expressed
Tlrs 1, 4, 7, 8, and 13), MHC class I and class II receptors,
as well as TLR-adaptor molecules, such as IRAK3 and
TICAM2 (Additional file 2: Figure S8A). TLRs signal to
the innate immune system to induce the death of inflamed
and damaged cells [107]. Glia, neurons, and neural pro-
genitor cells all express TLR2 and TLR4, and may contrib-
ute to the striking responsiveness of several glioma models
to metronomic CPA-induced anti-tumor immunity seen in
our studies. MHC class I receptors are normally expressed
on all nucleated cells, however, they are most abundant on
cytotoxic T and NK lymphocytes. MHC class II complexes
are present on many immune cells, in particular antigen-
presenting cells, such as innate immune macrophage and
dendritic cells and adaptive immune B cells [108]. IPA
network analysis showed a close association between in-
terferons and MHC class I molecules, β-2-microglobulin
and the antigen-processing molecule TAP (Additional
file 2: Figure S8B). MHC and T-cell receptor com-
plexes are also important for lymphocyte-mediated cy-
tolysis via the granzyme-perforin pathway (Additional
file 2: Figures S8B and S8C) [74]. While it is unclear from
our array analyses which cells specifically express thesereceptor complexes, these complexes should be consid-
ered as possible mediators of metronomic CPA-induced
anti-tumor immunity and tumor regression.
Conclusions
The mechanisms that govern the potent therapeutic re-
sponses to the intermittent metronomic CPA used here
are only partially understood, but most likely involve im-
munogenic cell death [69,70,109], which can stimulate
dendritic cell and CD8-T cell-based immune responses
leading to long-term immunity [16]. Tumors intrinsically
sensitive to CPA cytotoxicity but unresponsive to metro-
nomic CPA activation of anti-tumor immunity [27] likely
undergo non-immunogenic apoptosis. While CPA and
other drugs that activate immunogenic cell death are in-
creasingly being studied in combination with immunother-
apies [10,110,111], there is a pressing need for rational,
mechanistic approaches to determine optimal combina-
tions, doses and schedules. The present identification of
gene signatures of metronomic CPA responses and their
upstream regulators will help elucidate underlying mecha-
nisms and facilitate the development of clinically useful
biomarkers of tumor responsiveness; such markers will ul-
timately be required for translation to the clinic to identify
clinically effective metronomic regimens and responsive
patients. The gene signatures of responsiveness include
many genes known to be associated with innate immune
cell recruitment and activation, as well as many novel fac-
tors whose role in the actions of metronomic CPA are
poorly understood. Finally, our finding that metronomic
CPA also induces the expression of factors that counter
the tumor regression response, including several im-
munosuppressive factors, raises the possibility that such
factors may contribute to tumor escape from CPA-induced,
immune-based regression seen in some cases [13,15],
highlighting the need to identify the mechanisms in-
volved and then develop effective mechanisms to cir-
cumvent them.
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to Table 2. Table S3. Upstream regulators of human U251 genes; relates
to Table 3. Table S4. Detailed presentation of mouse microarray data for
metronomic CPA-treated U251 and 9L tumors. Table S5. Annotation
clusters of mouse genes up-regulated (Table S5A) or down-regulated
(Table S5B) in U251 and 9L tumors; relates to Table 4. Table S6. Upstream
regulators of differentially expressed mouse genes in metronomic
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genes in metronomic CPA-treated U251 and 9L tumors at late time
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to S8: Figure S1. Top network showing connections between
metronomic CPA-induced expression of TNF and cell death-related
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target pathway networks from upstream analysis, based on U251/human
array, involving: A) Human IFNG and downstream STAT and NFkB signaling.
B) Human IL27, an IPA-predicted upstream regulator. C) Mechanistic
network for IL27 and interferon and NFkB signaling. Figure S3.
PPARG gene network. Figure S4. Mouse gene upstream regulator analysis,
based on U251 tumors (CPA treatment day 12). Downstream target
networks for upstream regulators of responsive mouse genes: (A) IL12
complex, (B) mir-223, and (C) STAT1. Figure S5. Upstream regulator analysis
of late-responding mouse genes, based on CPA-treatment of U251 tumors
(day 18) and 9L tumors (day 24). Figure S6. Tumor cell activation of host
innate immune system responses: A) Interferon secretion and downstream
response gene pathways activated in damaged human U251 tumor cells.
B) Innate immune stimulatory interleukin-15 production linked to interferon
pathway activation and secretion. Figure S7. Canonical pathway related to
host innate immune system responses to metronomic CPA-damaged tumor
cells via complement component activation. Figure S8. Top networks
involving A) tumor necrosis factor and DNA damage response genes,
potentially leading to TLR or cytokine-based immune stimulation. B)
Major histocompatibility complex and interferon pathway genes
important for cell-to-cell signaling, immune activation, and targeted
immune-mediated cell death. C) Perforin-granzyme cytolytic pathway,
also related to T cell receptor (TCR) and MHC cell targeting.
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